Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NextCure, Inc.NXTC · Entity 7461 | SVP, Research | January 31, 2022 | February 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NextCure, Inc.
Report date January 31, 2022 · Filed February 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.57 · Expires 2032-01-30 | Direct | 65,600 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 65,600 · Balance 65,600 F1: One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2022 Filed Feb 2, 2022 21:22 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,600 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0000905148-22-000163 · form4.xml · derivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2032-01-30 F1 · derivative.exercise_date: One fourth of the option vests on January 31, 2023. The remainder vests in 36 monthly installments beginning on February 28, 2023. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:46 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001123292-21-000494 · edgar.xml · derivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: One fourth of the option vests on March 15, 2022. The remainder vests in 36 monthly installments beginning on April 15, 2022. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:36 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 39,100 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000459 · edgar.xml · derivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,100 Underlying: Common Stock · 39,100 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,745 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · derivative · entry 4 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,373 Underlying: Common Stock · 20,745 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One fourth of the option vested on March 15, 2018. The remainder vests in 36 monthly installments beginning on April 15, 2018. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,489 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · derivative · entry 3 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,076 Underlying: Common Stock · 34,489 shares Expires 2026-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One fourth of the option vested on September 1, 2017. The remainder vests in 36 monthly installments beginning on October 1, 2017. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionCommon Stock | 20,745 | $1.21 | $25,101.45 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · nonDerivative · entry 2 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2019 Filed Feb 21, 2020 21:11 UTC | NextCure, Inc. NXTC · Entity 7461 | Exercise / conversionCommon Stock | 34,489 | $0.48 | $16,554.72 |
DisclosureSEC source: 0001123292-20-000301 · edgar.xml · nonDerivative · entry 1 Liu Linda · CIK 0001775427 · SVP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.